New therapy for patients with advanced kidney cancer

The US Food and Drug Administration, (FDA) has approved a drug combination for initial treatment of patients with advanced renal cell carcinoma, the most common type of kidney cancer. This follows the FDA’s priority review of the results of a Phase 3 trial of combination of Merck Research Laboratories drug Keytruda with Pfizer’s Inlyta. Keytruda…